These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 11920636)

  • 1. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
    Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
    Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.
    Koch M; Hussein F; Woeste A; Gründker C; Frontzek K; Emons G; Hawighorst T
    Breast Cancer Res Treat; 2011 Jul; 128(2):337-46. PubMed ID: 20714802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body.
    Coronella J; Li L; Johnson K; Pirie-Shepherd S; Roxas G; Levin N
    Anticancer Res; 2009 Jun; 29(6):2243-52. PubMed ID: 19528489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
    Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
    Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
    Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
    Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.
    Rofstad EK; Henriksen K; Galappathi K; Mathiesen B
    Cancer Res; 2003 Jul; 63(14):4055-61. PubMed ID: 12874006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
    Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
    Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.
    Dawson DW; Volpert OV; Pearce SF; Schneider AJ; Silverstein RL; Henkin J; Bouck NP
    Mol Pharmacol; 1999 Feb; 55(2):332-8. PubMed ID: 9927626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.
    Rofstad EK; Galappathi K; Mathiesen B
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):493-9. PubMed ID: 14751520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.
    Iruela-Arispe ML; Lombardo M; Krutzsch HC; Lawler J; Roberts DD
    Circulation; 1999 Sep; 100(13):1423-31. PubMed ID: 10500044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo.
    Noh YH; Matsuda K; Hong YK; Kunstfeld R; Riccardi L; Koch M; Oura H; Dadras SS; Streit M; Detmar M
    J Invest Dermatol; 2003 Dec; 121(6):1536-43. PubMed ID: 14675207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.
    Jiménez B; Volpert OV; Crawford SE; Febbraio M; Silverstein RL; Bouck N
    Nat Med; 2000 Jan; 6(1):41-8. PubMed ID: 10613822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.
    Dawson DW; Pearce SF; Zhong R; Silverstein RL; Frazier WA; Bouck NP
    J Cell Biol; 1997 Aug; 138(3):707-17. PubMed ID: 9245797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
    Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.
    Chan LY; Craik DJ; Daly NL
    Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26464514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
    Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
    J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.
    Jeanne A; Boulagnon-Rombi C; Devy J; Théret L; Fichel C; Bouland N; Diebold MD; Martiny L; Schneider C; Dedieu S
    Clin Exp Metastasis; 2016 Oct; 33(7):637-49. PubMed ID: 27349907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.